Group: Biosimilars need unique CMS reimbursement codes
This article was originally published in Scrip
Executive Summary
Even though there may be several biosimilars that reference the same innovator drug, they should not be lumped into the same Medicare Part B reimbursement rate, a lobbying group is contending, in opposing a new rule proposed by the Obama administration.